We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Panel Tepidly Backs OK of Bladder Drug Despite Small Clinical Effect
Panel Tepidly Backs OK of Bladder Drug Despite Small Clinical Effect
April 25, 2012
The FDA’s Reproductive Health Drugs Advisory Committee is recommending approval of Astellas’ overactive bladder (OAB) drug mirabegron, saying unresolved cardiovascular safety concerns are outweighed by the need for new OAB therapies.